Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis

References

• Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33(8):1563–9.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int. 2012;82(8):840–56.
   PubMed Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–57.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–4.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–28.
   PubMed Web of Science ®Google Scholar
• Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ. Cyclosporin in the treatment of lupus nephritis. Am J Nephrol. 1989;9(1):57–60.
   PubMed Web of Science ®Google Scholar
• Hussein MM, Mooij JM, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol. 1993;40(3):160–3.
   PubMed Web of Science ®Google Scholar
• Dostál C, Tesar V, Rychlík I, Zabka J, Vencovský J, Bartûnková J, et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus. 1998;7(1):29–36.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kotani T, Takeuchi T, Isoda K, Hata K, Watanabe K, et al. Successful treatment of early intervention with tacrolimus for a patient with lupus nephritis III + V. Jpn J Clin Immunol. 2008;31(6):460–4.
   PubMedGoogle Scholar
• Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19(6):606–15.
   PubMed Web of Science ®Google Scholar
• Lee T, Oh KH, Joo KW, Kim YS, Ahn C, Han JS, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010;19(8):974–80.
   PubMed Web of Science ®Google Scholar
• Fei Y, Wu Q, Zhang W, Chen H, Hou Y, Xu D, et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. 2013;31(1):62–8.
   PubMed Web of Science ®Google Scholar
• Chatzidimitriou A, Trachana M, Pratsidou-Gertsi P. The role of tacrolimus in the step-up induction therapy of refractory childhood-onset lupus nephritis. Hippokratia. 2015;19(4):378.
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15–20.
   PubMed Web of Science ®Google Scholar
• Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247–97.
   PubMed Web of Science ®Google Scholar
• Foster MH. T cells and B cells in Lupus Nephritis. Semin Nephrol. 2007;27(1):47–58.
   PubMed Web of Science ®Google Scholar
• Zietse R, Wenting GJ, Kramer P, Mulder P, Schalekamp MA, Weimar W. Contrasting response to cyclosporin in refractory nephrotic syndrome. Clin Nephrol. 1989;31(1):22–5.
   PubMed Web of Science ®Google Scholar
• Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome. Clin Sci. 1992;82(6):641–50.
   PubMed Web of Science ®Google Scholar
• Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grünfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57–63.
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008;14(9):931–8.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(Suppl3):S1–S155.
   Google Scholar
• Shah S, Verma P. Overview of pregnancy in renal transplant patients. Int J Nephrol. 2016;2016:4539342.
   PubMed Web of Science ®Google Scholar
• Coscia LA, Constantinescu S, Moritz MJ, Frank AM, Ramirez CB, Maley WR, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010;24(1):65–85.
   Google Scholar
• Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, et al. Long-term treatment of lupus nephritis with cyclosporine A. Q J Med. 1998;91(8):573–80.
   Google Scholar
• Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova ED, et al. Treatment of lupus nephritis with cyclosporine – an outcome analysis. Kidney Blood Press Res. 2007;30(2):124–8.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–31.
   PubMed Web of Science ®Google Scholar
• Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol. 1996;35(7):669–75.
   PubMedGoogle Scholar
• Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum. 1994;37(4):551–8.
   PubMed Web of Science ®Google Scholar
• Caccavo D, Laganà B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. 1997;40(1):27–35.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and Validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2012;64(8):2677–86.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–50.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630–40.
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156–62.
   PubMed Web of Science ®Google Scholar
• Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephro. 2009;20(4):901–11.
   PubMed Web of Science ®Google Scholar
• Hu W, Liu Z, Shen S, Li S, Yao X, Chen H, Li L. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J. 2003;116(12):1827–30.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Snaith ML, Morrow WJ, Al-Khader AA, Cohen SL, Fisher C, et al. Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol. 1981;3(2):163–9.
   PubMed Web of Science ®Google Scholar
• Morton SJ, Powell RJ. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis. 2000;59(6):487–9.
   PubMed Web of Science ®Google Scholar